Format

Send to:

Choose Destination
See comment in PubMed Commons below
Clin Dev Immunol. 2013;2013:875343. doi: 10.1155/2013/875343. Epub 2013 Nov 26.

Radioimmunotherapy combined with maintenance anti-CD20 antibody may trigger long-term protective T cell immunity in follicular lymphoma patients.

Author information

  • 1Department of Nuclear Medicine, Lausanne University Hospital, 1011 Lausanne, Switzerland ; Department of Nuclear Medicine, Geneva University Hospitals, 1211 Geneva, Switzerland.
  • 2Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • 3Department of Biochemistry, University of Lausanne, 1066 Lausanne, Switzerland.
  • 4Department of Hematology, Geneva University Hospitals, 1211 Geneva, Switzerland.
  • 5Department of Oncology, Geneva University Hospitals, 1211 Geneva, Switzerland.
  • 6Department of Oncology, Lausanne University Hospital, 1011 Lausanne, Switzerland.
  • 7Department of Nuclear Medicine, Lausanne University Hospital, 1011 Lausanne, Switzerland.
  • 8Ludwig Center, Department of Oncology, Lausanne University Hospital, 1011 Lausanne, Switzerland.

Abstract

Growing evidence suggests that the patient's immune response may play a major role in the long-term efficacy of antibody therapies of follicular lymphoma (FL). Particular long-lasting recurrence free survivals have been observed after first line, single agent rituximab or after radioimmunotherapy (RIT). Rituximab maintenance, furthermore, has a major efficacy in prolonging recurrence free survival after chemotherapy. On the other hand, RIT as a single step treatment showed a remarkable capacity to induce complete and partial remissions when applied in recurrence and as initial treatment of FL or given for consolidation. These clinical results strongly suggest that RIT combined with rituximab maintenance could stabilize the high percentages of patients with CR and PR induced by RIT. While the precise mechanisms of the long-term efficacy of these 2 treatments are not elucidated, different observations suggest that the patient's T cell immune response could be decisive. With this review, we discuss the potential role of the patient's immune system under rituximab and RIT and argue that the T cell immunity might be particularly promoted when combining the 2 antibody treatments in the early therapy of FL.

PMID:
24371449
[PubMed - indexed for MEDLINE]
PMCID:
PMC3858978
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Hindawi Publishing Corporation Icon for PubMed Central
    Loading ...
    Write to the Help Desk